News & Articles
Discover our latest news features, insightful blog posts, and important updates from AuctuCel.
AuctuCel Signs MOU with StellarCell Bio to Advance Exosome and Cell Culture Research
(From left) Mr. Zhou, Chief Strategy Officer of StellarCell Bio; Ms. Guo, General Manager of StellarCell Bio; together with Dr Fhu Chee Wai, Co-founder and Chief Executive Officer of AuctuCel, and Dr Zach Pang, Co-founder and Chief Scientific Advisor of AuctuCel, at the MOU signing ceremony to strengthen collaboration in cell culture and bioprocess optimisation. We’re pleased to share that AuctuCel has signed an MOU with StellarCell BioMedicine Inc. (星誠細胞生醫) , a Taiwan-based company focused on regenerative medicine and cell therapy. Under this collaboration, AuctuCel will provide our serum-free and xeno-free specialised media to support StellarCell Bio’s exosome and extracellular vesicle (EV) culture research. Research outcomes will be shared between both teams, with the potential for joint publications. Where needed, we will also support culture media optimisation to meet performance requirements.
Syarikat Spin-off A*STAR BTI, AuctuCel lancar platform AI
Mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus. SINGAPURA, 12 September 2025 – AuctuCel, syarikat bioteknologi baharu hasil spin-off daripada A*STAR Bioprocessing Technology Institute (BTI) melancarkan platform proprietari dikenali sebagai Fluxperior iaitu satu sistem berkuasa kecerdasan buatan (AI) yang dibangunkan bagi mengurangkan kos dan masa dalam menghasilkan resipi nutrien untuk pertumbuhan sel yang digunakan dalam rawatan perubatan. Dibangunkan oleh penyelidik A*STAR BTI, Fluxperior menggabungkan pemodelan komputer dengan AI untuk meramal keperluan nutrien sel secara tepat, sekali gus menggantikan kaedah tradisional berasaskan proses cuba jaya yang kebiasaannya mengambil masa lebih enam bulan. Hasil kajian menunjukkan Fluxperior mampu mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus.
Singapore's A*STAR BTI spinoff AuctuCel launches AI platform to slash cell medicine production costs by 80%
Image Caption: left to right: Lingesh Kumar, Scientific and Operations Manager of AuctuCel, Dr Fhu Chee Wai, Co-founder & CEO of AuctuCel, Prof Andy Hor, Deputy Chief Executive (Research), A*STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A*STAR, Dr Zach Pang, Co-founder & Chief Scientific Officer of AuctuCel Enterprise Singapore's Startup SG program has awarded AuctuCel $65,000 to develop an innovative product built on BTI's expertise in culture media development, bioprocess analytics, and computational modeling. AuctuCel, a biotech spin-off from Singapore's A*STAR Bioprocessing Technology Institute (BTI), has officially launched with its proprietary Fluxperior platform — an artificial intelligence-powered system designed to dramatically reduce the cost and time required to develop nutrient “recipes” for growing cells used in medical treatments. Developed by A*STAR BTI researchers, Fluxperior combines computer modelling with AI to predict exactly what nutrients cells need to thrive, replacing the traditional trial-and-error process that typically takes more than six months. Proven results show Fluxperior can cut development costs by up to 80%, speed up timelines by 83%, and boost cell productivity by more than 20%.
AuctuCel Celebrates First Anniversary with Official Launch and Strategic Milestones
Image Caption: left to right: Lingesh Kumar, Scientific and Operations Manager of AuctuCel, Dr Fhu Chee Wai, Co-founder & CEO of AuctuCel, Prof Andy Hor, Deputy Chief Executive (Research), A*STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A*STAR, Dr Zach Pang, Co-founder & Chief Scientific Officer of AuctuCel AuctuCel, a pioneering biotech spin-off from Singapore’s A*STAR Bioprocessing Technology Institute, marked its first anniversary with a launch event on 9 September 2025, bringing together industry leaders, scientists, investors, and partners from across the region. In just one year since incorporation, AuctuCel has achieved significant milestones that underscore its vision of transforming biomanufacturing with precision and innovation. The event was graced by Prof Andy Hor, Deputy Chief Executive (Research), A STAR, and A/Prof Andre Choo, Deputy Executive Director, Bioprocessing Technology Institute, A STAR, who shared their presence and speeches.
AuctuCel has signed an MoU with Shimadzu (Asia Pacific) to advance cell culture media optimisation and drive innovation in biomanufacturing
Featuring from left to right: Sandhya Nargund | Prem Anand | Chee Wai Fhu | Boon Tong Koh We’re beyond excited to share this big milestone 🎉 — AuctuCel has signed an MoU with Shimadzu (Asia Pacific) to advance cell culture media optimisation and drive innovation in biomanufacturing. It’s an honour to collaborate with a global science leader like Shimadzu, made even more meaningful as it coincides with Shimadzu Corporation’s 150th anniversary — a remarkable legacy of scientific excellence. At AuctuCel , we use computational modelling and AI-powered design to create next-generation culture media that make development faster, smarter, and easier to scale. By integrating our digital media design platform with Shimadzu’s advanced analytical technologies and modelling capabilities, we’re unlocking deeper insights, improving precision, and paving the way for smarter, faster media innovation.
New startup AuctuCel uses AI to slash cell medicine manufacturing costs
AuctuCel founders, Zach Pang (left) and Chee Wai Fhu (right) By harnessing technology to optimise how cells are grown, AuctuCel is able to production costs and timelines for cell therapies, potentially making treatments more accessible and affordable. Singapore-based biotechnology start-up AuctuCel has officially launched with a system that uses technology to make cell medicine manufacturing more efficient, reducing time and money spent from research and development (R&D) to manufacturing. The start-up is a spin-off of Agency for Science, Technology and Research’s ( A*STAR ) Bioprocessing Technology Institute (BTI). AuctuCel’s flagship platform, Fluxperior, uses both computer modelling with artificial intelligence (AI) to determine the precise mix of nutrients that cells need to thrive in the lab. Typically, cells are grown in mediums, and the ideal composition for each type of cell is typically determined through trial-and-error. This can take more than six months of costly testing. According to AuctuCel, Fluxperior can reduce development costs by up to 80%, shorten timelines by up to 83%, and boost cell productivity by more than 20%. This has major implications for cell-based therapies. Stem cells and other manufactured cell types form the foundation for a wide range of treatments, including transplants for blood-related conditions such as anaemia, leukaemia, lymphoma, and certain inherited immune disorders.
